natgillin/translations-raw huggingface dataset:
However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered.
Olanzapín sa má použ opatrne u pacientov so záchvatmi v anamnéze alebo u tých, ktorí sú ívať vystavení faktorom, ktoré môž zniž
These symptoms can temporally deteriorate or even arise after discontinuation of treatment.
Vo väčine týchto prípadov boli v anamnéze prítomné záchvaty alebo iné rizikové faktory.
Postural hypotension Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials.
Posturálna hypotenzia V klinických štúdiách olanzapínu sa zriedka u starš pacientov pozorovala posturálna hypotenzia.
As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years.
U ích pacientov starš ako 65 rokov sa, tak ako u ostatných antipsychotík, odporúč pravidelne merať krvný tlak.
Use in children and adolescents under 18 years of age Olanzapine is not indicated for use in the treatment of children and adolescents.
Š preukázali rozlič než
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels.
iaduce reakcie, vrátane zvýš telesnej hmotnosti, zmien metabolických enia
Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1).
enia sú známe (pozri č 4. 8 a 5. 1). asti
5 Lactose Zalasta tablets contain lactose.
5 Tablety Zalasta obsahujú laktózu.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Pacienti so zriedkavými dedič nými problémami galaktózovej intolerancie, Lappovej deficiencie laktázy alebo malabsorpcie glukózo- galaktózy nemajú už tento ívať liek.
4.5 Interaction with other medicinal products and other forms of interaction
špecificky indukovať alebo inhibovať tento izoenzým, môž ovplyvniť
Interaction studies have only been performed in adults.
farmakokinetiku olanzapínu.
Potential interactions affecting olanzapine Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.
metabolizmus olanzapínu, č môž následne viesť Fajč a karbamazepín môž indukovať zníž
Induction of CYP1A2 The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations.
u Pozorovali sa zanedbateľ prípadne len né,
Only slight to moderate increase in olanzapine clearance has been observed.
klírensu olanzapínu.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).
Hoci klinický dopad je pravdepodobne minimálny, odporúč sa klinické a monitorovanie a v nevyhnutných prípadoch je mož zváž zvýš dávok olanzapínu (pozri č 4. 2).
Inhibition of CYP1A2 Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
Inhibícia CYP1A2 Preukázalo sa, ž fluvoxamín, š
The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non- smokers and 77% male smokers.
Priemerné zvýš maximálnej koncentrácie (Cmax) olanzapínu fluvoxamínom bolo enie 54% u ž nefajč
The mean increase in olanzapine AUC was 52% and 108% respectively.
koncentrácie (AUC) olanzapínu bolo 52% u ž nefajč
A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin.
už ívajúcich fluvoxamín, prípadne iný inhibítor CYP1A2, ako napr. ciprofloxacín, sa má zvážiť zníž poč nej dávky olanzapínu.
A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP 1A2 is initiated.
Zníž biologickej dostupnosti enie Aktívne uhlie zniž biologickú dostupnosť
Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.
má už minimálne 2 hodiny pred, resp. po podaní olanzapínu. ívať
Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.
Fluoxetín (inhibítor CYP2D6), jednorazové dávky antacida (s obsahom hliníka, horč alebo íka) cimetidín, nemali signifikantný vplyv na farmakokinetiku olanzapínu.
Potential for olanzapine to affect other medicinal products Olanzapine may antagonise the effects of direct and indirect dopamine agonists.
Olanzapín môž antagonizovať inky priamych a nepriamych agonistov dopamínu.
1A2, 2D6, 2C9, 2C19, 3A4).
1A2, 2D6, 2C9, 2C19, 3A4). akávajú sa preto žiadne osobitné interakcie, č dokazujú aj in vivo š Ne
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).
inhibíciu metabolizmu nasledovných aktívnych látok: tricyklických antidepresív (reprezentujúcich prevaž CYP2D6 cestu metabolizácie), warfarínu (CYP2C9), teofylínu (CYP1A2) alebo diazepamu ne (CYP3A4 a 2C19).
Olanzapine showed no interaction when co-administered with lithium or biperiden.
Olanzapín nevykazoval ž iadnu interakciu so súbež podávaným lítiom alebo biperidenom. ne
Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Monitorovanie terapeutických plazmatických hladín valproátu neukázalo, ž by pri zač prídavnej medikácie olanzapínom bola pož adovaná úprava dávkovania valproátu.
General CNS activity Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.
Všeobecná CNS aktivita Opatrnosť potrebná u pacientov konzumujúcich alkohol alebo už
The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).
Súbež už né ívanie olanzapínu s antiparkinsonikami u pacientov s Parkinsonovou chorobou a demenciou sa neodporúč (pozri č 4. 4).
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
6 Opatrnosť potrebná, ak sa olanzapín podáva súbež s liekmi, ktoré predlž QTc interval (pozri č 4. 4). asť
There are no adequate and well-controlled studies in pregnant women.
Avš vzhľ
Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine.
poč gravidity len vtedy, ak jeho potenciálny prínos pre matku prevýšmož riziko pre plod.
Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
iaduce udalosti ako tras, hypertónia, letargia a ospalosťu
Spontaneous reports have been very rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
detí narodených matkám, ktoré už olanzapín v treť trimestri.
In a study in lactating, healthy women, olanzapine was excreted in breast milk.
Priemerná ien oval
Mean infant exposure (mg/ kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/ kg).
expozícia dieť a (mg/ kg) v rovnováž stave bola odhadnutá na 1, 8% z dávky olanzapínu podanej
Patients should be advised not to breast feed an infant if they are taking olanzapine.
Pacientky je potrebné pouč o tom, ž poč lieč olanzapínom nesmú dojč svoje dieť a.
4.7 Effects on ability to drive and use machines
opatrní pri obsluhe strojov, vrátane
No studies on the effects on the ability to drive and use machines have been performed.
vedenia motorových vozidiel.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Dospelí iaduce reakcie (pozorované u ≥1% pacientov) spojené s už Najč astejš hlásené než
4.8 Undesirable effects
ívaním olanzapínu
Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
akatízia, parkinsonizmus (pozri č 4. 4), dyskinéza, ortostatická hypotenzia, anticholinergné úč prechodné asymptomatické zvýš peč a edém.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
asť ových transamináz (pozri č 4. 4), vyráž asténia, únava enie eň asť ka,
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V rámci jednotlivých skupín frekvencií sú nežiaduce úč usporiadané inky nosti.
Very common (≥
Veľ č (10%), č v poradí klesajúcej závaž
10%), common (≥ 1% and < 10%), uncommon (≥ 0.1% and < 1%), rare (≥ 0.01% and
(≥1% a < 10%), menej č (≥0, 1% and < 1%), zriedkavé (≥0, 01% a < 0, 1%), veľ zriedkavé (< 0, 01%), neznáme (nemož
< 0.1%), very rare (< 0.01%), not known (cannot be estimated from the data available).
asté odhadnúť dostupných údajov). no z
Very common
Menej č
Uncommon
asté
Blood and the lymphatic system disorders Immune system disorders
Ochorenia krvi a lymfatického systému
Thrombocytopenia Allergic reaction
Trombocytopénia
Metabolism and nutrition
Poruchy imunitného systému
disorders
Alergická reakcia
Weight gain1
Zvýš telesnej
Elevated cholesterol levels 2,3 Elevated glucose levels 4 Elevated triglyceride levels 2,5 Glucosuria Increased appetite
enie
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4) Hypothermia
Zvýš
Nervous system disorders Somnolence
hladiny ené
Dizziness Akathisia6
hmotnosti1
Seizures where in most cases a history of
cholesterolu 2, 3 Zvýš hladiny ené
Cardiac disorders
Závrat Akatízia6
Parkinsonism6 Dyskinesia 6
Parkinsonizmus6 Dyskinéza 6
seizures or risk factors for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
Neuroleptický malígny syndróm (pozri č 4. 4) asť Dystónia (vrátane kruhových pohybov oč ných gúľ) Tardívna dyskinéza Symptómy z vysadenia7
Vascular disorders
Ochorenia srdca a poruchy srdcovej č innosti
Bradycardia QT c prolongation (see section 4.4)
Bradykardia ž QT c Predĺ enie (pozri č 4. 4) asť
Ventricular tachycardia/ fibrillation, sudden death (see section 4.4)
Ventrikulárna tachykardia/ fibrilác ia, náhle úmrtie (pozri č 4. 4) asť
Mild, transient anticholinergic effects including constipation and dry mouth
Mierne, prechodné anticholinergné úč vrátane inky zápchy a sucha v
Hepato-biliary disorders
Ochorenia peč a ž ových ciest ene lč
Transient, asymptomatic elevations of hepatic transaminases (ALT, AST), especially in early treatment (see section 4.4)
Hepatitída (vrátane hepatocelulárneho, cholestatického
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
eň transamináz (ALT, AST), hlavne na zač iatku lieč by (pozri č 4. 4) asť
Skin and subcutaneous tissue disorders
alebo zmieš aného poš kodenia)
Rash
ené
Photosensitivity reaction Alopecia
fosfokináza Zvýš celkový ený bilirubín
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels 8 1
Nárast telesnej hmotnosti ≥7% pôvodnej telesnej hmotnosti bol veľ č a ≥15% pôvodnej telesnej hmotnosti bol č
High creatine phosphokinase Increased total bilirubin
boli vyšie u pacientov bez predtým dokázanej lipidovej dysregulácie.
Increased alkaine phosphatase
9 3 Pozorované pri normálnych hladinách nalač na zač
Clinically significant weight gain was observed
iatku (< 5, 17 mmol/ l), ktoré sa zvýš na ili
across all baseline Body Mass
hladinu vysokú (≥6, 2 mmol/ l).
Index (BMI)
hodnoty (≥ 4
categories.
mi asté.
15% of baseline body
olanzapínom. by
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
Súvisiace klinické prejavy (napr. gynekomastia, galaktorea a zväčenie prsníkov) boli zriedkavé. š U väčiny pacientov sa hladiny upravili do normálneho stavu po skonč lieč
4 Observed for fasting normal levels at baseline (< 5.56 mmol/ l) which increased to high (≥ 7 mmol/ l).
Dlhodobá expozícia (aspoň týž ov) 48 dň Pomer pacientov, u ktorých sa vyskytli než
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/ l - < 2.26 mmol/ l) to high (≥ 2.26 mmol/ l) were very common.
iaduce, klinicky signifikantné zmeny týkajúce sa hmotnostného prírastku, glukózy, celkového/ LDL/ HDL cholesterolu alebo triglyceridov sa č asom zvýš U dospelých pacientov, ktorí absolvovali 9- 12 mesač terapiu, sa rýchlosť enia
6 In clinical trials, the incidence of parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
priemernej hladiny krvnej glukózy spomalila približ po 4- 6 mesiacoch. ne
Olanzapine-treated patients had a lower incidence of parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol.
Ď ie informácie o zvláš alš tnych populáciách V klinických š túdiách u starš pacientov s demenciou bola pri lieč olanzapínom v porovnaní
In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it can not be concluded at present that olanzapine produces less tardive dyskinesia and/ or other tardive extrapyramidal syndromes.
s placebom vyš incidencia úmrtí a cerebrovaskulárnych než Veľ
7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.
ívaní olanzapínu u tejto skupiny pacientov boli abnormálna chôdza a pády.
8 Associated clinical manifestations (e. g., gynaecomastia, galactorrhoea, and breast enlargement) were rare.
Č boli pozorované pneumónia, zvýš telesná teplota, letargia, erytém, zrakové
In most patients, levels returned to normal ranges without cessation of treatment.
halucinácie a inkontinencia moč u.
Long-term exposure (at least 48 weeks) The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/ LDL/ HDL cholesterol or triglycerides increased over time.
V klinických štúdiách u pacientov s liekmi vyvolanou psychózou (dopamínovým agonistom) súvisiacou s Parkinsonovou chorobou, boli veľ č a s vyšou frekvenciou ako u placeba š mi asto zaznamenané zhorš parkinsonovskej symptomatiky a halucinácie. enie
In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 4-6 months.
V jednej klinickej š u pacientov v manickej fáze bipolárnej poruchy bola pri lieč valproátom
Additional information on special populations In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
v kombinácii s olanzapínom incidencia neutropénie 4, 1%; potenciálne prispievajúcim faktorom by mohli byť vysoké plazmatické hladiny valproátu.
Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
Súbež podanie olanzapínu s lítiom alebo né valproátom viedlo ku zvýš výskytu (10%) tremoru, suchosti v ústach, zvýš chuti do jedla
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Č boli zaznamenané aj poruchy reč Poč lieč olanzapínom
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’ s disease, worsening of Parkinsonian symptomatology and ha llucinations were reported very commonly and more frequently than with placebo.
v kombinácii s lítiom alebo divalproexom doš v akútnej fáze lieč (do 6 týž ov) k nárastu telesnej
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
Dlhodobá lieč
Olanzapine administered with lithium or valproate resulted in increased levels ( 10%) of tremor, dry mouth, increased appetite, and weight gain.
olanzapínom (do 12 mesiacov) na prevenciu rekurencie u pacientov s bipolárnou poruchou bola ením telesnej hmotnosti o  v porovnaní s poč nou hodnotou u 39, 9% spojená so zvýš pacientov.
Speech disorder was also reported commonly.
10 Olanzapín nie je indikovaný na lieč detí a mladistvých pacientov do 18 rokov.
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
žiadne klinické štúdie porovnávajúce mladistvých pacientov s dospelými, údaje získané zo š túdií s mladistvými pacientmi boli porovnané s údajmi získanými zo š s dospelými pacientami. túdií
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of  from baseline body weight in 39.9% of 7% patients.
iaduce reakcie hlásené s vyšou frekvenciou u mladistvých
9 Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
pacientov (vo veku 13 – 17 rokov) ako u dospelých pacientov alebo než
Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
Zdá sa, ž klinicky
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients.
významný prírastok na hmotnosti (≥7%) sa vyskytuje č
Clinically significant weight gain (≥ 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
dospelými pri porovnateľ ných expozíciách.
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Výš hmotnostného prírastku a pomer adolescentných ka š pacientov, u ktorých bol klinicky signifikantný hmotnostný prírastok, bol vyš pri dlhodobej expozícii í (aspoň týž ov) ako pri krátkodobej expozícii.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V rámci jednotlivých skupín frekvencií sú nežiaduce úč usporiadané v poradí klesajúcej inky nosti.
Very common (≥ 10%), common (≥ 1% and < 10%).
Veľ č (10%), č (≥1% a < 10%). závaž
Metabolism and nutrition disorders Very common:
Poruchy metabolizmu a výž Veľ č
Weight gain9, elevated triglyceride levels10, increased appetite.
Hmotnostný prírastok9, zvýš hladina triglyceridov10, zvýš chuť jedla.
11 Common:
Č asté:
Elevated cholesterol levels Nervous system disorders Very common:
Zvýš hladina cholesterolu11 ená Poruchy nervového systému Veľ č
Gastrointestinal disorders Common:
Gastrointestinálne poruchy Č asté:
Dry mouth Hepato-biliary disorders Very common:
Suchosť ústach. v Poruchy peč a ž ových ciest ene lč Veľ č mi asté:
Elevations of hepatic transaminases (ALT/ AST; see section 4.4).
Vyš etrenia Veľ č
Investigations Very common:
mi asté:
Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
Zníž celkového bilirubínu, zvýš GMT, zvýš plazmatickej hladiny prolaktínu12.
9 Weight gain ≥ 7% of baseline body weight (kg) was very common and ≥ 15% of baseline body weight was common.
(kg) sa vyskytoval veľ
With long-term exposure (at least 24 weeks), approximately half of adolescent patients gained ≥ 15% and almost a third gained ≥ 25% of their baseline body weight.
24 týž ov), približ polovica adolescentných pacientov dosiahla ≥15% a takmer tretina dosiahla
Among adolescent patients, mean weight gain was greatest in patients who were overweight or obese at baseline.
≥25% nárastu ich pôvodnej telesnej hmotnosti.
10 Observed for fasting normal levels at baseline (< 1.016 mmol/ l) which increased to high (≥ 1.467 mmol/ l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/ l - < 1.467 mmol/ l) to high (≥ 1.467 mmol/ l).
≥1, 467 mmol/ l a zmeny triglyceridov nalač z hranič poč nej hodnoty (≥1, 016 mmol/ l - < 1, 467 mmol/ l) na ≥1, 467 mmol/ l.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - < 5.17 mmol/ l) to high (≥ 5.17 mmol/ l) were very common.
poč nej hodnoty (≥4, 39 - < 5, 17 mmol/ l) na ≥5, 17 mmol/ l sa vyskytovali veľ č 12
12 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
Zvýš plazmatickej hladiny prolaktínu bolo hlásené u 47, 4% mladistvých pacientov. enie
Signs and symptoms Very common symptoms in overdose (> 10% incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Príznaky a symptómy Medzi veľ č príznaky predávkovania (výskyt > 10%) patrí tachykardia, agitácia/ agresivita, mi asté dyzartria, rôzne extrapyramídové príznaky a zníž stupeň
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (< 2% of overdose cases) and cardiopulmonary arrest.
neuroleptický malígny syndróm, útlm dýchania, aspirácia, hypertenzia alebo hypotenzia, srdcová arytmia (< 2% prípadov predávkovania) a zástava dýchania a č innosti srdca.
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of 1,500 mg.
Smrteľ prípady sa né vyskytli už akútnom predávkovaní dávkou 450 mg, ale takisto bolo popísané prež po akútnom
10 Management of overdose There is no specific antidote for olanzapine.
11 Pre olanzapín neexistuje ž iadne špecifické antidotum.
Induction of emesis is not recommended.
Neodporúč sa vyvolávanie vracania.
Standard procedures for management of overdose may be indicated (i. e. gastric lavage, administration of activated charcoal).
ívané pri lieč predávkovania (tj. výplach be
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.
olanzapínu po perorálnom podaní o 50- 60%.
Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function.
Podľ klinického stavu je potrebné zač symptomatickú lieč a monitorovanie vitálnych funkcií,
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension.
Nepouž ívajte epinefrín,
Cardiovascular monitoring is necessary to detect possible arrhythmias.
kvôli diagnostike mož ných porúch srdcového rytmu.
Close medical supervision and monitoring should continue until the patient recovers.
Pacient má byť do zotavenia pod stálou až lekárskou kontrolou a majú byť sledované aj jeho vitálne funkcie.